Evidence map›Paper›PMID 34986798›Full record

ReviewBMC cardiovascular disorders2022

Fatal pulmonary tumour thrombotic microangiopathy in patient with ovarian adenocarcinoma: review and a case report.

Gintare Neverauskaite-Piliponiene, Kristijonas Cesas, Darius Pranys, Skaidrius Miliauskas, Lina Padervinskiene, Jolanta Laukaitiene, Giedre Baksyte, Gintare Sakalyte, Egle Ereminiene

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in BMC cardiovascular disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Pulmonary Hypertension in the Field of Hematological and Oncological Diseases.Respiration; international review of thoracic diseases · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Gintare Neverauskaite-PiliponieneDepartment of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307, Kaunas, Lithuania. gintare.neverauskaite@gmail.com.ORCID 0000-0001-5149-087X
Kristijonas CesasDepartment of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307, Kaunas, Lithuania.
Darius PranysDepartment of Pathology, Medical Academy, Lithuanian University of Health Sciences, 44307, Kaunas, Lithuania.
Skaidrius MiliauskasDepartment of Pulmonology, Medical Academy, Lithuanian University of Health Sciences, 44307, Kaunas, Lithuania.
Lina PadervinskieneDepartment of Radiology, Medical Academy, Lithuanian University of Health Sciences, 44307, Kaunas, Lithuania.
Jolanta LaukaitieneDepartment of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307, Kaunas, Lithuania.
Giedre BaksyteDepartment of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307, Kaunas, Lithuania.
Gintare SakalyteDepartment of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307, Kaunas, Lithuania.
Egle EreminieneDepartment of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307, Kaunas, Lithuania.
Lithuanian University of Health Sciences · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulmonary tumour thrombotic microangiopathy (PTTM) is a fatal disease in which tumour cells embolize to the pulmonary vasculature leading to pulmonary hypertension and right heart failure. Early diagnosis is essential for timely treatment which can reduce intimal pulmonary vascular proliferation and prolong survival, improve the symptoms. Due to rare occurrences and no clear diagnostic guidelines the disorder usually is found post-mortem. We present a review of this rare disease and a case of post-mortem diagnosed pulmonary tumour thrombotic microangiopathy in a young female. CASE PRESENTATION: 51 years old woman presented with progressively worsening dyspnea, right ventricular failure signs and symptoms. Computerized tomography denied pulmonary embolism. 2D transthoracic echocardiography demonstrated right ventricle dilatation and dysfunction, severely increased systolic pulmonary pressure. Right heart catheterization revealed pre-capillary pulmonary hypertension with mean pulmonary artery pressure of 78 mmHg, pulmonary wedge pressure of 15 mmHg, reduced cardiac output to 1.78 L/min with a calculated pulmonary vascular resistance of 35 Wood units, and extremely low oxygen saturation (26%) in pulmonary artery. Because of worsening ascites, pelvic magnetic resonance imaging was performed, tumours in both ovaries were diagnosed. Due to the high operative risk, detailed tumour diagnosis surgically was not established. The patient developed progressive cardiorespiratory failure, unresponsive to optimal heart failure drug treatment. A postmortem morphology analyses revealed tumorous masses in pre-capillary lung vessels, right ventricle hypertrophy, ovary adenocarcinoma.

conclusionsAn early diagnosis of PTTM is essential. Most cases are lethal due to respiratory failure progressing rapidly. Patients with a history of malignancy, symptoms and signs implying of PH should be considered of having PTTM. If detected early enough, combination of chemotherapy with specific PH therapy is believed to be beneficial in reducing intimal proliferation and prolonging survival, along with improving the symptoms.

Indexed as

AdenocarcinomaFatal OutcomeFemaleHumansLungLung NeoplasmsMiddle AgedNeoplastic Cells, CirculatingOvarian NeoplasmsPulmonary EmbolismThrombotic MicroangiopathiesTomography, X-Ray ComputedOvary adenocarcinomaPulmonary tumour thrombotic microangiopathyRight heart failure

Identifiers

PMID34986798
PMCPMC8729036
OpenAlexW4205115642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.